![The 5 Most Significant Lab Company M&A Deals of 2022](https://www.g2intelligence.com/wp-content/uploads/2023/01/Jan10-2023.News_.TopMandADeals-iStock-1800x1250-1-1080x675.jpg)
The 5 Most Significant Lab Company M&A Deals of 2022
Merger and acquisition deal volume and value were down last year, but deal impact was not.
Merger and acquisition deal volume and value were down last year, but deal impact was not.
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.
Here are what G2 Intelligence considers to be the 10 most significant FDA lab testing clearances of 2022, in rough chronological order.
The total market for PCR products will likely top $5 billion in 2023, according to a new report.
M&A activity in the clinical diagnostics space was significantly down in 2022 in terms of both deal volume and deal value.